Drug intelligence / Profile preview

Inactivated Polio Vaccine (Star Biotech)

Development stage: Unknown
Lead developer: StarBio
Modality: Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

StarBio's Inactivated Polio Vaccine (IPV) is an approved vaccine indicated for the prevention of poliomyelitis. It is an inactivated (Salk) vaccine that contains killed poliovirus strains, typically covering types 1, 2, and 3. The vaccine works by inducing the production of neutralizing antibodies against the poliovirus, providing protective immunity and preventing the virus from causing paralytic disease. It is administered via injection and is a key component of immunization programs aimed at global polio eradication.

Other names: IPVInactivated Polio (Salk) Vaccine

Beyond the preview

Go deeper on Inactivated Polio Vaccine (Star Biotech).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inactivated Polio Vaccine (Star Biotech).

Explore the full profile